CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$2.47 USD
+0.09 (3.57%)
Updated May 20, 2024 03:58 PM ET
After-Market: $2.41 -0.06 (-2.23%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Can-Fite Biopharma Ltd [CANF]
Reports for Purchase
Showing records 141 - 160 ( 216 total )
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Transferring Coverage at Buy and $6 Price Target
Provider: Rodman & Renshaw, Co.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
A Next-Generation Approach to Treating Autoimmune Disease and Cancer; Transferring Coverage at Buy and $6 Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Phase 3 Rheumatoid Arthritis Trial Protocol Submitted to EMA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Phase 3 Rheumatoid Arthritis Study Takes Shape; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
3Q15 Update: Dual Phase 3 Trials Slated for 2016 Initiation; Raising PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
CF102 Eyes Expansion into NASH, Piclidenoson Remains Value Driver
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
We are dropping coverage to focus our efforts elsewhere in the Biotechnology sector
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
2Q15 Update-Pivotal Piclidenoson Protocols Could Drive Shareholder Value
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
1Q15 UpdateLate Onset Benefit Could Be Captured in Next Psoriasis Trial
Provider: H.C. WAINWRIGHT & CO., INC.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
1Q15 Results; Anticipating Next Stages in Psoriasis Program
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.